Research Analysts Set Expectations for ATXS FY2024 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Astria Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn ($1.74) per share for the year, up from their prior forecast of ($1.82). HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.62) EPS.

ATXS has been the topic of a number of other research reports. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer increased their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, TD Cowen assumed coverage on Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Astria Therapeutics has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Down 7.1 %

Shares of ATXS stock opened at $9.37 on Monday. The firm has a market cap of $528.79 million, a P/E ratio of -4.48 and a beta of 0.71. The company has a 50 day moving average of $11.40 and a 200-day moving average of $10.62. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90.

Institutional Trading of Astria Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ATXS. Quest Partners LLC grew its holdings in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 2,861 shares during the period. PDT Partners LLC purchased a new stake in shares of Astria Therapeutics during the third quarter worth about $140,000. SG Americas Securities LLC purchased a new stake in shares of Astria Therapeutics in the 3rd quarter worth about $155,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Astria Therapeutics during the 2nd quarter valued at about $171,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.